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Abstract 
Purpose: 
The purpose of this systematic review is to provide up-to-date evidence on effectiveness of 
antiarrhythmic drugs for shockable cardiac arrest to help inform the 2018 International Liaison 
Committee on Resuscitation Consensus on Science with Treatment Recommendations.   
Methods: 
A search was conducted in electronic databases Medline, Embase, and Cochrane Library from 
inception to August 15, 2017.   
Results: 
 
Of the 9,371 citations reviewed, a total of 14 RCTs and 17 observational studies met our 
inclusion criteria for adult population and only 1 observational study for pediatric population. 
Based on RCT level evidence for adult population, none of the anti-arrhythmic drugs showed 
any difference in effect compared with placebo, or with other anti-arrhythmic drugs for the 
critical outcomes of survival to hospital discharge and discharge with good neurological 
function. For the outcome of return of spontaneous circulation, the results showed a significant 
increase for lidocaine compared with placebo (RR=1.16; 95% CI, 1.03 to 1.29, p=0.01). 
Conclusion: 
 
The high level evidence supporting the use of antiarrhythmic drugs during CPR for shockable 
cardiac arrest is limited and showed no benefit for critical outcomes of survival at hospital 
discharge, survival with favorable neurological function and long-term survival. Future high 
quality research is needed to confirm these findings and also to evaluate the role of administering 
 
 
antiarrhythmic drugs in children with shockable cardiac arrest, and in adults immediately after 
ROSC.   
Key Words:  Cardiac arrest, pulseless ventricular tachycardia or ventricular fibrillation, 
antiarrhythmic drugs, good neurological function, return of spontaneous circulation. 
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Introduction 1 
 2 
Cardiac arrest (CA) is defined as sudden and unexpected loss of heart function accompanied with 3 
loss of breathing and consciousness primarily due to disturbance in electrical activity of heart. 4 
An estimated 320,000 to 700,000 cases of out-of-hospital cardiac arrests (OHCA) occur annually 5 
across the United States and Europe [1, 2].  CA with an initial heart rhythm of pulseless 6 
ventricular tachycardia or ventricular fibrillation (pVT/VF) is the most treatable cause of CA [2]. 7 
For those individuals who receive cardiopulmonary resuscitation (CPR) with prompt shock 8 
treatment (i.e. defibrillation) and drugs, if needed, only 8-40% survive to hospital discharge [3-9 
8]. Of these, approximately 50-75% have favourable neurological outcome, although about 50% 10 
of survivors likely have subtle cognitive deficits [9, 10].   11 
 12 
A recent systematic review and meta-analysis comparing amiodarone and lidocaine with placebo 13 
demonstrated that both drugs showed increased survival to hospital admission compared with 14 
placebo, however, neither drug showed any benefit on long-term survival or good neurological 15 
outcomes for adults [11]. For pediatric CA, a 2017 systematic review found weak evidence to 16 
recommend the use of amiodarone or lidocaine for shock-resistant pVT/VF in infants and 17 
children [12]. The American Heart Association guidelines published in 2015, recommend the use 18 
of amiodarone with lidocaine as an alternative to amiodarone for pVT/VF for adults 19 
unresponsive to CPR, defibrillation or vasopressor therapy [13].  20 
 21 
However, to-date, the evidence synthesis on anti-arrhythmic drugs used to treat CA, has been 22 
primarily based on randomized controlled trials that are likely underpowered and prone to bias 23 
with unbalanced baseline characteristics, different drug formulation and timing of drug 24 
2 
 
administration [14, 15].  This warrants the need to update and systematically review any 25 
potential new available evidence that may impact results and conclusions. The purpose of this 26 
systematic review and meta-analysis is to provide the most up-to-date evidence on effectiveness 27 
of antiarrhythmic drugs for shockable cardiac arrest in both adults and children, and help inform 28 
the updated 2018 International Liaison Committee on Resuscitation (ILCOR) Consensus on 29 
Science with Treatment Recommendations (CoSTR).   30 
 31 
Methods 32 
 33 
The protocol for this review was published on PROSPERO on December 15, 2017 registration 34 
number CRD42017080475. The same methods have been used by and are reported in other 35 
publications authored by our review team [16-18]. 36 
Review question 37 
Among adults and children (neonates, children and adolescents < 18) in any setting (in-hospital 38 
or out-of-hospital) with cardiac arrest and a shockable rhythm at any time during 39 
cardiopulmonary resuscitation (CPR) or immediately after return of spontaneous circulation 40 
(ROSC), does administration of antiarrhythmic drugs (e.g., amiodarone, lidocaine, other), 41 
compared with another antiarrhythmic drug or placebo or no drug , change outcomes of  survival 42 
to hospital discharge with good neurological outcome, survival to hospital discharge, ROSC and  43 
recurrence of recurrence of pVT/VF? 44 
Search Strategy 45 
A search was conducted in electronic databases Medline, Embase, and Cochrane Library from 46 
inception to August 15, 2017.  Reference lists from relevant systematic reviews were searched 47 
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for studies missed by the electronic search. The electronic search identified 13,868 citations and 48 
8 additional citations were found through other sources (e.g., reference list check). Once 49 
duplicates were removed, there were 9,371 citations uploaded to the web-based screening 50 
program [19] to be screened independently by review staff.  51 
Study Selection, data abstraction and quality assessment 52 
Two reviewers independently selected studies for possible inclusion.  Studies selected by either 53 
reviewer based on title and abstract underwent full text review.  At the level of full text 54 
screening, any disagreement was discussed between reviewers and a third party was involved to 55 
help reach consensus, as necessary (see Table 1 for inclusion criteria).  Full data extraction, 56 
including characteristics of included studies and risk of bias (assessed using the Cochrane risk of 57 
bias framework [20] was completed by one reviewer and verified by a second reviewer. 58 
Disagreements were resolved between the two reviewers with a third party involvement to reach 59 
consensus, as necessary. In case of multiple publications from same study, the first publication 60 
was considered as main reference while the outcome data was extracted across all publications 61 
and the most recent outcome data was considered for analyses. The Grading of 62 
Recommendations Assessment, Development and Evaluation (GRADE) system [21] was used to 63 
assess the strength and the quality of evidence using GRADEPro software [22]. The quality of 64 
outcome-based bodies of evidence was assessed for risk of bias due to limitations in design, 65 
indirectness, inconsistency of findings, imprecision, and reporting bias (such as publication bias).  66 
Meta-analyses were conducted where appropriate. 67 
Data synthesis 68 
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For the primary outcomes of effectiveness of antiarrhythmic drugs in adults and children with 69 
SCA (i.e. survival at discharge, survival at discharge with good neurological function, long-term 70 
survival, ROSC, and cardiac re-arrest) we used number of events to generate the summary 71 
measures of effect in the form of risk ratio (RR) using DerSimonian and Laird [23] random 72 
effects models with Mantel-Haenszel method.  The primary grouping of studies in each meta-73 
analysis was based on type of population i.e. adult or pediatric, and type of study design (RCT or 74 
observational). Further subgrouping was done based on type of anti-arrhythmic drug and drug 75 
comparison (placebo or head-to-head trials).  76 
To evaluate statistical stability, robustness of results and to account for any potential bias (such 77 
as confidence intervals being inappropriately wide) in pooled estimates, we performed sensitivity 78 
analysis based on type of pooling method i.e. DerSimonian-Laird random-effects model (REM), 79 
Fixed-effects model (FEM), and Peto one-step odds ratio [24, 25]. The sensitivity analyses did 80 
not reveal any noticeable differences in effect estimates based on type of pooling method used. 81 
The Cochran’s Q (α=0.05) was employed to detect statistical heterogeneity and I2 statistic to 82 
quantify the magnitude of statistical heterogeneity between studies where I2 30% to 60% 83 
represents moderate and I2 60% to 90% represents substantial heterogeneity across studies [26].  84 
All analyses were performed using Review Manager (RevMan Version 5.3) [27], STATA 85 
(version 14) [28] and GRADEpro Guideline Development Tool software packages [22].  86 
Results 87 
Overall Search Results 88 
Of the 9,371 citations reviewed, 34 unique citations met the inclusion criteria and were selected 89 
for this review. There are 14 randomized and controlled clinical trial studies (16 papers) and 18 90 
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observational studies (21 papers) addressing the questions for adults and 1 observational study 91 
for the pediatrics (see fig. 1 for Flow Diagram).  92 
Summary of Included Studies for the Adult Population 93 
A total of 14 RCTs [29-42] and 18 observational studies [43-60] were included. The overall risk 94 
of bias for RCTs was rated high in one study [42], unclear in eleven studies [29-35, 37, 39-41], 95 
and low in two studies [36, 38]. The individual domain ratings for each study are reported in 96 
Supplemental File 1. The Newcastle-Ottawa Quality Assessment Scale was used to rate the 97 
quality of the included observational studies and no major quality concerns were identified (see 98 
Supplemental File 1).  The publication years of resuscitation guidelines applied in the RCT 99 
studies ranged from pre-2000 to 2010 and the publication years of resuscitation guidelines 100 
referenced in the observational studies ranged from pre-2000 to 2015 (see Supplemental File 2).  101 
The included RCTs were comprised of one study [38] with a large sample (>1,000 participants), 102 
one study [37] with a medium sized sample (500-999 participants), and twelve studies [29-36, 103 
39-42] with small samples (<499 participants).  In the observational studies, there were four [44, 104 
48, 49, 58] large cohorts (>1,000 participants), four [43, 50, 57, 60] medium sized cohorts (500-105 
999 participants), and ten [45-47, 51-56, 59] small cohorts (<499 participants).  The range of 106 
mean ages in the included RCT studies was 57 to 67 years, while in the observational studies it 107 
was 55.8 to 83.3 years. Most of the RCT and observational studies included more males than 108 
females. All the RCTs administered the intervention drug during CPR. In the studies time of 109 
administration was reported [29-31, 37, 38, 41], time from cardiac arrest to first dose of the trial 110 
drug ranged from 10 to 30 minutes. All but one observational study administered the intervention 111 
drug during CPR while one administered the drug immediately after ROSC.  The time from 112 
cardiac arrest to first dose of the trial drug was reported in six studies [51-54, 57, 59] and ranged 113 
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from 6 to 35 minutes. Additional information on the characteristics of included studies can be 114 
found in Supplemental File 2. 115 
Anti-arrhythmic drugs versus Placebo (RCT-level evidence) 116 
Amiodarone versus Placebo 117 
The evidence on amiodarone was considered as both pooled and separated. The primary reason 118 
to look at evidence separately was the different drug formulations (i.e. amiodarone with or 119 
without polysorbate 80) and placebo comparator (i.e. active polysorbate 80 placebo and inactive 120 
saline placebo) active across the two included studies. The vasoactive solvent “polysorbate 80 121 
“in Cordarone™ preparation of amiodarone has been linked to potential adverse hemodynamic 122 
effects particularly bradycardia and hypotension and may be associated with differential effect 123 
on outcomes of interest based on drug formulation [61, 62]. For the critical outcome of survival 124 
with favorable neurologic function at hospital discharge, the pooled evidence showed no 125 
difference in effect for amiodarone compared with placebo (2 RCTs; RR=1.13; 95% CI, 0.95 to 126 
1.36, p=0.18, I2=0%) [37, 38]. The overall quality of evidence was rated as very low quality and 127 
downgraded for serious concerns for risk of bias, indirectness and imprecision. The evidence on 128 
amiodarone in polysorbate 80, i.e. the Cordarone™ preparation of amiodarone, with very low 129 
quality (downgraded for serious concerns for risk of bias, indirectness and imprecision), showed 130 
no difference in effect for amiodarone compared with an active polysorbate 80 placebo (1 RCT; 131 
RR=1.11; 95% CI, 0.59 to 2.10, p=0.75) [37]. The evidence on the Nexterone™ preparation of 132 
amiodarone, with moderate quality (downgraded for serious concerns for imprecision), showed 133 
no difference in effect for amiodarone compared with inactive “saline” placebo (1 RCT; 134 
RR=1.13; 95% CI, 0.94 to 1.37, p=0.19, (see Table 2, fig. 2.1) [38]. 135 
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For the critical outcome of survival at hospital discharge, the pooled evidence showed no 136 
difference in effect for amiodarone compared to placebo (2 RCTs; RR=1.14; 95% CI 0.98 to 137 
1.33, p=0.08, I2=0%) [37, 38]. The overall quality of evidence was rated as very low quality and 138 
downgraded for serious concerns for risk of bias, indirectness and imprecision. Evidence on the 139 
Cordarone™ preparation of  amiodarone, with very low quality (downgraded for serious 140 
concerns for risk of bias, indirectness and imprecision), showed no difference in effect for 141 
amiodarone compared with an active polysorbate 80 placebo (1 RCT; RR=1.02; 95% CI, 0.65 to 142 
1.59, p=0.94) [37]. Evidence on Nexterone™ preparation of amiodarone, with moderate quality 143 
(downgraded for serious concerns for imprecision), showed no difference in effect for 144 
amiodarone compared with inactive saline placebo (1 RCT; RR=1.16; 95% CI, 0.99 to 1.37, 145 
p=0.07, see Table 2, fig. 2.2) [38].  146 
For the important outcome of ROSC, the pooled evidence showed no difference in effect for 147 
amiodarone compared with placebo (2 RCTs; RR=1.13; 95% CI, 0.93 to 1.37, p=0.11, I2=60%) 148 
[37, 38]. The overall quality of evidence was rated as very low quality and downgraded for 149 
serious concerns for risk of bias, indirectness and imprecision. Evidence on the Cordarone™ 150 
preparation of amiodarone, with very low quality (downgraded for serious concerns for risk of 151 
bias, indirectness and imprecision), showed benefit favoring amiodarone compared with an 152 
active polysorbate 80 placebo (1 RCT; RR=1.27; 95% CI, 1.02 to 1.59, p=0.03) [37]. Evidence 153 
on Nexterone™ preparation of amiodarone, with moderate quality (downgraded for serious 154 
concerns for imprecision), showed no difference in effect for amiodarone compared with inactive 155 
saline placebo (1 RCT; RR=1.04; 95% CI, 0.92 to 1.17, p=0.52, see Table 2, fig. 2.3) [38]. 156 
Lidocaine versus Placebo 157 
For the critical outcome of survival with favorable neurological function at hospital discharge, 158 
the effect estimate showed no difference in effect for lidocaine compared with placebo (1 RCT; 159 
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RR=1.05; 95% CI, 0.87 to 1.28, p=0.59, see Table 3, fig. 2.1) [38]. Similar results were obtained 160 
for the critical outcome of survival at hospital discharge (1 RCT; RR=1.13; 95% CI, 0.96 to 1.32, 161 
p=0.15, see Table 3, fig. 2.2) [38]. The overall quality of this evidence was rated as moderate and 162 
downgraded for serious concerns regarding imprecision. 163 
For the important outcome of ROSC, the effect estimate showed a significant increase favoring 164 
lidocaine compared with placebo (1 RCT; RR=1.16; 95% CI, 1.03 to 1.29, p=0.01, see fig. 2.3) 165 
[38]. The overall quality of this evidence was rated as high. 166 
Other anti-arrhythmic drugs versus Placebo 167 
For the critical outcome of survival with favorable neurological function at hospital discharge, 168 
the pooled effect estimate showed no difference in effect for magnesium compared with placebo 169 
(3 RCTs; RR=2.08; 95% CI, 0.87 to 4.97, p=0.10, I2=0%, see Supplemental File 3, fig. 2.1) [30, 170 
32, 41]. Similar results were obtained for the outcomes of survival to discharge for magnesium 171 
(4 RCTs; RR=1.07; 95% CI, 0.62 to 1.86, p=0.81, I2=0%) [30, 32, 33, 41] and bretylium (1 RCT; 172 
RR=4.28; 95% CI, 0.60 to 30.26, p=0.15, see Supplemental File 3, fig. 2.2) [40]; and ROSC for 173 
magnesium (4 RCTs; RR=0.97; 95% CI, 0.77 to 1.24, p=0.83, I2=0%, see Supplemental File 3, 174 
fig. 2.3) [30, 32, 33, 41]. The overall quality of this evidence was rated as very low and 175 
downgraded for serious concerns regarding risk of bias and imprecision.  176 
Head-to-head comparisons (RCT-level evidence) 177 
Amiodarone versus Lidocaine 178 
For the critical outcome of survival with favorable neurological function at hospital discharge, 179 
the evidence with moderate quality (downgraded for serious concerns for imprecision) showed 180 
no difference in effect for amiodarone compared with lidocaine (1 RCT; RR=1.08; 95%CI 0.89 181 
to 1.30, p=0.44, see Table 4, fig. 3.1) [38].  182 
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For the critical outcome of survival to hospital discharge, the pooled evidence showed no 183 
difference in effect for amiodarone compared with lidocaine (2 RCTs; RR=1.04; 95% CI 0.89 to 184 
1.22, p=0.59, I2=0%) [31, 38]. Evidence on lidocaine with the use of polysorbate 80, showed no 185 
difference in effect for amiodarone compared with lidocaine (1 RCT; RR=1.67; 95% CI, 0.57 to 186 
4.88, p=0.35) [31]. The overall quality of evidence was rated as very low quality and 187 
downgraded for serious concerns for risk of bias, indirectness and imprecision. Evidence on 188 
critical outcome of survival to hospital discharge for lidocaine without use of polysorbate 80, 189 
with moderate quality (downgraded for serious concerns for imprecision), showed no difference 190 
in effect for amiodarone compared with lidocaine (1 RCT; RR=1.03; 95% CI, 0.88 to 1.21, 191 
p=0.69, see Table 4, fig. 3.2) [38].  192 
 Similar results were obtained for the important outcome of ROSC (1 RCT; RR=0.90; 95% CI, 193 
0.80 to 1.01, p=0.07, see Table 4, fig. 3.3) [38]. The overall quality of this evidence was rated as 194 
moderate and downgraded for serious concerns regarding imprecision.  195 
Other anti-arrhythmic drugs head-to-head comparisons  196 
For the critical outcomes of survival with favorable neurological function at discharge, survival 197 
at discharge, cardiac re-arrest and ROSC, none of the effect estimates for anti-arrhythmic drug 198 
head-to-head comparisons showed any difference in effect (see Supplemental File 4, figs. 3.1 to 199 
3.4), except ROSC for lidocaine vs. nifekalant where the difference was marginally significant 200 
favoring lidocaine (RR=0.23; 95% CI, 0.06 to 0.92, p=0.04, see Supplemental File 4, fig. 3.3) 201 
[35]. However, the study was under-powered with very small sample size. The overall quality of 202 
this evidence was rated as low to very low and downgraded for serious concerns regarding risk 203 
of bias and imprecision. 204 
Anti-arrhythmic drugs versus no antiarrhythmic drugs (standard care; observational 205 
studies) 206 
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Amiodarone versus standard care 207 
For the critical outcomes of survival at hospital discharge and the long-term survival of 1 year, 208 
one large cohort study [48] (n=24,899) showed significant difference in effect favoring 209 
amiodarone compared with standard care (RR=2.88; 95% CI, 2.58 to 3.21, p<0.001; and 210 
RR=2.53; 95% CI, 2.26 to 2.84, p<0.001, respectively, see figs. 4.1 and 4.2). The smaller cohort 211 
study [55] (n=290) showed no difference in effect for either survival to hospital discharge or 212 
ROSC (p>0.05, see figs. 4.1 and 4.3).  213 
Lidocaine versus standard care 214 
For the outcomes of survival to  hospital discharge and the long-term survival of 1 year, one 215 
large cohort study [48] (n=19,517) showed significant difference in effect favoring lidocaine 216 
compared with standard care (RR=2.52; 95% CI, 2.04 to 3.12, p<0.001; and RR=2.19; 95% CI, 217 
1.74 to 2.75, p<0.001, respectively, see figs. 4.1 and 4.2). Another cohort study [47] (n=290) also 218 
showed significant difference in effect for the outcome ROSC favoring lidocaine compared with 219 
standard care (RR=1.88; 95% CI, 1.29 to 2.75, p=0.001). However, the observed effect was non-220 
significant for survival at hospital discharge and ROSC across two relatively small cohort studies 221 
(n=853, p>0.05, see figs 4.1 and 4.3) [46, 60]. 222 
Other anti-arrhythmic drugs versus standard care 223 
For the outcomes of survival with favorable neurological function at hospital discharge, survival 224 
at discharge, cardiac re-arrest and ROSC, none of the effect estimates for other anti-arrhythmic 225 
drugs showed any difference in effect compared with standard care (see figs. 4.1, 4.3, and 4.4) 226 
except ROSC for procainamide in one cohort study [50] where the difference was significant 227 
favoring procainamide (RR=0.59; 95% CI, 0.42 to 0.82, p=0.02).  228 
Head-to-head comparisons (observational studies) 229 
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Amiodarone versus Lidocaine 230 
For the outcome of survival at hospital discharge, the pooled evidence across 5 cohort studies 231 
[44, 48, 52, 53, 58] (n=11,263) showed no difference in effect for amiodarone compared with 232 
lidocaine (RR=0.87; 95% CI, 0.72 to 1.06, p=0.17, see fig. 5.1). For the outcome of long-term 233 
survival of 1 year, one large cohort study (n=7,536) showed no difference in effect for 234 
amiodarone compared with lidocaine (RR=1.16; 95% CI, 0.92 to 1.46, p=0.22, see fig. 5.2) [48]. 235 
Similar results were obtained for the outcome of ROSC across 3 cohort studies (n=2425; 236 
RR=0.79; 95% CI, 0.63 to 1.00, p=0.05, see fig. 5.3) [43, 44, 52]. 237 
Other anti-arrhythmic drugs head-to-head comparisons  238 
For the outcome of survival with favorable neurological function at hospital discharge, none of 239 
the effect estimates for other head-to-head comparisons showed any difference (see fig. 5.4). For 240 
the outcome of survival at hospital discharge, one small cohort study [57] (n=230) showed 241 
significant difference favoring lidocaine compared with procainamide (RR=0.31; 95% CI, 0.11 242 
to 0.86, p=0.006). For the outcome of long-term survival of 1 year, one large cohort study [48] 243 
(n=9,023) showed significant difference favoring combined use of amiodarone plus lidocaine 244 
compared with amiodarone or lidocaine alone (RR=1.34; 95% CI, 1.14 to 1.58, p<0.001; and 245 
RR=1.55; 95% CI, 1.20 to 2.01, p<0.001, respectively). For the outcome of ROSC, the pooled 246 
evidence across 3 cohort studies [43, 45, 58] showed marginally significant difference favoring 247 
nifekalant compared with amiodarone (n=1,000; RR=0.92; 95% CI, 0.86 to 0.99, p=0.03). 248 
Another small cohort study [57] (n=230) also showed significant difference favoring lidocaine 249 
compared with procainamide (RR=0.55; 95% CI, 0.34 to 0.90, p=0.02, see fig. 5.3). 250 
Adults with cardiac arrest and a shockable rhythm immediately after return of 251 
spontaneous circulation 252 
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No RCT level evidence was identified that answered this question, however 1 observational 253 
study [49] provided data on adults with cardiac arrest and prophylactic antiarrhythmic drugs 254 
given within 1 hour of ROSC. For the outcome of survival to hospital discharge, the results 255 
based on non-propensity matched cohorts (lidocaine arm: 1296; standard care: 425) showed a 256 
significant effect favoring the administration of prophylactic lidocaine compared with standard 257 
care (RR= 1.40, 95% CI 1.25, 1.57; p<0.0001). However, the effect was non-significant when 258 
data from propensity matched cohorts (lidocaine arm: 400; standard care: 400) was used 259 
(RR=1.03, 95% CI 0.89, 1.20; p=0.67). For the outcome of recurrence of pVT/VF, the results 260 
showed a significant effect favoring the administration of prophylactic lidocaine compared with 261 
standard care for both non-propensity matched cohorts with 55% reduction (RR= 0.45, 95% CI 262 
0.38, 0.53; p<0.0001) and propensity matched cohorts with 41% reduction (RR= 0.59, 95% CI 263 
0.47, 0.74; p<0.0001).  264 
Pediatric Population 265 
 266 
There was one observational study involving children that met our criteria for inclusion [63]. 267 
There were no major concerns regarding risk of bias. The study focused on a cohort of 889 268 
participants <18 years of age. The sex of participants was not reported. The trial drug was 269 
administered during cardiac arrest. The time from cardiac arrest to first dose of the drug was not 270 
reported. 271 
Infants and children with cardiac arrest and a shockable rhythm at any time during 272 
cardiopulmonary resuscitation (CPR) or immediately after return of spontaneous 273 
circulation) 274 
No RCT level evidence was identified that answered this question, however, 1 observational 275 
study [63] provided data on in-hospital pediatric cardiac arrest and a shockable rhythm.  276 
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Amiodarone versus standard care 277 
For the outcomes of survival at hospital discharge and ROSC, one cohort study [63] (n=594) 278 
showed no difference in effect for amiodarone compared with standard care (RR=0.83; 95% CI, 279 
0.50 to 1.35, p=0.45; and RR=0.85; 95% CI, 0.66 to 1.09, p=0.21, respectively, see figs. 5.5 and 280 
5.6).  281 
Lidocaine versus standard care 282 
For the outcomes of survival at discharge, one cohort study [63] (n=718) showed no difference in 283 
effect for lidocaine compared with standard care (RR=1.24; 95% CI, 0.93 to 1.66, p=0.14, see 284 
fig. 5.5). However, the results showed significant difference in effect for the outcome ROSC 285 
favoring lidocaine compared with standard care (RR=1.24; 95% CI, 1.09 to 1.41, p=0.001, see 286 
fig. 5.6). 287 
The evidence for antiarrhythmic drug comparison with standard care should be interpret with 288 
caution as study was not clear about whether patients did not receive an anti-arrhythmic because 289 
they did not have shock refractory VF or because the care providers elected not to receive it.   290 
Lidocaine versus Amiodarone 291 
For the critical outcome of survival to hospital discharge, one cohort study [63] (n=302) found 292 
no difference in effect for lidocaine compared with amiodarone (25% versus 17%; P=NS; RR 293 
1.50; 95% CI 0.90 to 2.52, p=0.12, see fig. 5.7). However, the results showed significant increase 294 
in ROSC for lidocaine as compared with amiodarone (RR=1.46; 95% CI 1.13 to 1.88, p=0.004, 295 
see fig. 5.8).  296 
The study reported results for combined use of amiodarone and lidocaine compared with 297 
amiodarone or lidocaine alone and found no differences in effect for the outcome of survival to 298 
hospital discharge or ROSC (see figs. 5.7 and 5.8).  299 
 300 
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Discussion 301 
Our review found limited high level evidence (RCTs) supporting the use of antiarrhythmic drugs 302 
during CPR in adults with shock refractory pVT/VF and found no significant benefit for critical 303 
outcomes of survival at hospital discharge, survival with favorable neurological function and 304 
long-term survival. No high level evidence was identified for use of antiarrhythmic drugs in 305 
adults with shock refractory pVT/VF immediately after return of spontaneous circulation and in 306 
children with shockable cardiac arrest. 307 
 Summary of evidence 308 
Effectiveness of antiarrhythmic drugs in adults with cardiac arrest (shockable rhythm) at any 309 
time during cardiopulmonary resuscitation 310 
Most of the studies in our review included adults with cardiac arrest and a shockable rhythm at 311 
any time during CPR for out-of-hospital cardiac arrest, and no studies for in in-hospital cardiac 312 
arrest.  Based on RCT level evidence, none of the anti-arrhythmic drugs showed any difference 313 
in effect compared with placebo, or with other anti-arrhythmic drugs for the critical outcomes of 314 
survival to hospital discharge and discharge with good neurological function. The quality of 315 
evidence across these studies was rated from moderate to very low with concerns of risk of bias, 316 
indirectness and imprecision. For the important outcome of ROSC, the results showed a 317 
significant increase in ROSC for lidocaine compared with placebo (RR=1.16; 95% CI, 1.03 to 318 
1.29, p=0.01). The overall quality of this evidence was rated as high. The evidence on the 319 
Cordarone™ preparation of  amiodarone also showed marginal benefit for ROSC favoring 320 
amiodarone compared with an active polysorbate 80 placebo (RR=1.27; 95% CI, 1.02 to 1.59, 321 
p=0.03); however, the quality of the evidence was rated as very low with concerns for risk of 322 
bias, indirectness (active placebo with potential adverse hemodynamic effects) and imprecision. 323 
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The evidence from large observational study [48] (n=27,463) showed a significant benefit for 324 
amiodarone and lidocaine for the outcomes of survival at hospital discharge and long-term 325 
survival at 1-year. However, the effect estimates are based on raw events and subject to selection 326 
bias with imbalance across groups and should be interpret with caution. The results from smaller 327 
observational studies were inconsistent and likely underpowered with most showing no 328 
difference in effect for the outcomes of survival at discharge, survival at discharge with 329 
neurological function and ROSC.  330 
Effectiveness of antiarrhythmic drugs in adults with cardiac arrest (shockable rhythm) 331 
immediately after return of spontaneous circulation 332 
We found no RCT level evidence for this population, however, one observational study [49] 333 
(N=1,721) provided results for the use of prophylactic lidocaine compared with standard care 334 
within 1 hour of ROSC. The results from propensity matched cohort showed no difference in 335 
effect for the outcome of survival to hospital discharge; however, a significant reduction of 41% 336 
was observed for the outcome of recurrent pVT/VF. 337 
Effectiveness of antiarrhythmic drugs in children with cardiac arrest (shockable rhythm) 338 
We found no RCT level evidence for this population, however, one observational study [63] 339 
(N=889) compared the use of amiodarone, lidocaine, amiodarone plus lidocaine, and standard 340 
care for in-hospital pediatric cardiac arrest and a shockable rhythm. The results showed no 341 
differences in effect for the outcome of survival to hospital discharge. The evidence on ROSC 342 
showed a significant benefit for lidocaine compared with amiodarone. However, the comparisons 343 
are based on raw events and subject to selection bias with imbalance across groups and should be 344 
interpreted with caution. 345 
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Implications for clinical practice and future research 346 
These results will be considered by the Advanced Life Support (ALS) Task Force of the 347 
International Liaison Committee on Resuscitation and will be used to update treatment 348 
recommendations on the use of antiarrhythmic drugs in shock refractory pVT/VF. The use of 349 
antiarrhythmic drugs is just one aspect of the treatment of pVT/VF. Other interventions such as 350 
the quality of CPR, use of additional defibrillation attempts, extracorporeal CPR  (ECPR) 351 
techniques and percutaneous coronary intervention (PCI) during CPR are all likely to have a role 352 
in the improving survival from shock refractory pVT/VF arrest in adults . Future high quality 353 
research is needed to evaluate the effectiveness of administering antiarrhythmic drugs in adults 354 
with cardiac arrest immediately after ROSC and in children in cardiac arrest or immediately after 355 
ROSC. Future randomized controlled studies are also needed to explore the role of administering 356 
antiarrhythmic drugs in adults with in-hospital shockable cardiac arrest. 357 
Limitations 358 
First, there was considerable heterogeneity across studies for various population and study level 359 
factors such as dose and formulation of antiarrhythmic drugs, timing of drug administration, type 360 
of placebo (active or saline), sample size, setting (in or out-of-hospital), assessment of 361 
neurological function, type of standard care provided, resuscitation guidelines used, and timing 362 
of events. Second, there was insufficient high-level evidence to answer several questions of 363 
interest including effectiveness of anti-arrhythmic drugs in adults with cardiac arrest 364 
immediately after ROSC, for in-hospital cardiac arrest and in children with shockable cardiac 365 
arrest during CPR or immediately after ROSC.  Third, we did not analyze the differential 366 
effectiveness based on time lapsed from cardiac arrest to drug administration i.e. early or late in 367 
terms of EMS or bystander witnessed cardiac arrest. Fourth, the majority of included studies 368 
were under-powered with inadequate number of events or sample sizes to detect clinically 369 
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important differences, and results were imprecise with wide confidence intervals. Fifth, there 370 
was insufficient evidence to understand etiology based subgroups differences i.e. primary rhythm 371 
disorders (inherited, drug induced, congenital heart disease) versus coronary artery diseases.  372 
Finally, there were insufficient number of studies reporting outcomes of interest to assess 373 
publication bias.  374 
Conclusions 375 
 376 
The high level evidence supporting the use of antiarrhythmic drugs during CPR for shock 377 
refractory pVT/VF or immediately after ROSC is limited and showed no significant benefit for 378 
critical outcomes of survival at hospital discharge, survival with favorable neurological function 379 
and long-term survival. The high level evidence also showed a significant increase in important 380 
outcome of ROSC for lidocaine compared with placebo, suggesting that use of lidocaine during 381 
CPR may improve the short-term survival in adult cardiac arrest patients with shock refractory 382 
pVT/VF. However, future high quality research is needed to confirm these findings and also 383 
evaluate the effectiveness and role of administering antiarrhythmic drugs in children with 384 
shockable cardiac arrest, and in adults immediately after ROSC.  385 
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Table 1 553 
Inclusion Criteria 554 
Population Adults and children in any setting (in-hospital or out-of-hospital) with cardiac 
arrest and a shockable rhythm at any time during cardiopulmonary 
resuscitation (CPR) or immediately after Return of Spontaneous Circulation 
(ROSC). 
Intervention Administration (intravenous or intra-osseous) of an antiarrhythmic drug 
during CPR and immediately after ROSC. 
Comparators Another anti-arrhythmic drug or placebo or no drug during CPR or 
immediately after ROSC. 
Outcomes Any clinical outcome. 
Study Designs Randomised controlled trials (RCTs) and non-randomised studies (non-
randomised controlled trials, interrupted time series, controlled before-and-
after studies, cohort studies) are eligible for inclusion. All years and all 
languages are included as long as there is an English abstract; unpublished 
studies (e.g., conference abstracts, trial protocols) are excluded. 
 555 
 556 
 557 
 558 
 559 
 560 
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Table 2 
Question: Amiodarone compared with Placebo for shockable cardiac arrest in adults 
 Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk 
of bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Amiodarone Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
Survival to hospital discharge - combined 
2 a randomised 
trials  
serious 
b 
not serious  very serious 
c 
serious d none  270/1216 
(22.2%)  
256/1314 
(19.5%)  
RR 1.14 
(0.98 to 
1.33)  
27 more 
per 
1,000 
(from 4 
fewer to 
64 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Survival to hospital discharge - Cordarone preparation of Amiodarone 
1 e randomised 
trials  
serious 
f 
not serious  very serious 
g 
serious d none  33/246 
(13.4%)  
34/258 
(13.2%)  
RR 1.02 
(0.65 to 
1.59)  
3 more 
per 
1,000 
(from 46 
fewer to 
78 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Survival to hospital discharge - Nexterone preparation of Amiodarone  
1 h randomised 
trials  
not 
serious  
not serious  not serious  serious d none  237/970 
(24.4%)  
222/1056 
(21.0%)  
RR 1.16 
(0.99 to 
1.37)  
34 more 
per 
1,000 
(from 2 
fewer to 
78 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Survival to hospital discharge with good Neurological function - combined 
7 
 
 Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk 
of bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Amiodarone Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
2 a randomised 
trials  
serious 
b 
not serious  very serious 
c 
serious d none  200/1213 
(16.5%)  
192/1313 
(14.6%)  
RR 1.13 
(0.95 to 
1.36)  
19 more 
per 
1,000 
(from 7 
fewer to 
53 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Survival to hospital discharge with good Neurological function - Cordarone preparation of Amiodarone 
1 e randomised 
trials  
serious 
f 
not serious  very serious 
g 
serious d none  18/246 
(7.3%)  
17/258 
(6.6%)  
RR 1.11 
(0.59 to 
2.10)  
7 more 
per 
1,000 
(from 27 
fewer to 
72 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Survival to hospital discharge with good Neurological function - Nexterone preparation of Amiodarone  
1 h randomised 
trials  
not 
serious  
not serious  not serious  serious d none  182/967 
(18.8%)  
175/1055 
(16.6%)  
RR 1.13 
(0.94 to 
1.37)  
22 more 
per 
1,000 
(from 10 
fewer to 
61 more)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Return of Spontaneous Circulation (ROSC) - combined 
2 a randomised 
trials  
serious 
b 
not serious  very serious 
c 
serious d none  458/1220 
(37.5%)  
455/1317 
(34.5%)  
RR 1.13 
(0.93 to 
1.37)  
45 more 
per 
1,000 
(from 24 
fewer to 
128 
more)  
⨁◯◯◯ 
VERY LOW  
IMPORTANT  
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 Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studies 
Study 
design 
Risk 
of bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Amiodarone Placebo 
Relative 
(95% 
CI) 
Absolute 
(95% CI) 
Return of Spontaneous Circulation (ROSC) - Cordarone preparation of Amiodarone 
1 e randomised 
trials  
serious 
f 
not serious  very serious 
g 
serious i none  108/246 
(43.9%)  
89/258 
(34.5%)  
RR 1.27 
(1.02 to 
1.59)  
93 more 
per 
1,000 
(from 7 
more to 
204 
more)  
⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Return of Spontaneous Circulation (ROSC) - Nexterone preparation of Amiodarone  
1 h randomised 
trials  
not 
serious  
not serious  not serious  serious d none  350/974 
(35.9%)  
366/1059 
(34.6%)  
RR 1.04 
(0.92 to 
1.17)  
14 more 
per 
1,000 
(from 28 
fewer to 
59 more)  
⨁⨁⨁◯ 
MODERATE  
IMPORTANT  
CI: Confidence interval; RR: Risk ratio 
Explanations 
a. 1) Kudenchuk, 1999; 2) Kudenchuk, 2016.  
b. Serious concerns for risk of bias in one of the studies.  Kudenchuk, 1999 had unclear ratings for allocation concealment and blinding, and high other risk of bias (baseline 
imbalance, industry funcding etc.) 
c. Kudenchuk, 1999 used the Cordarone preparation of amiodarone vs. an active placebo (polysorbate 80), while Kudenchuk 2016 used the Nexterone preparation of amiodarone 
vs. saline (inactive) placebo.  
d. The effect estimate is imprecise with confidence intervals including the no effect value “1” and the sample size does not meet the optimal information size criteria.  
9 
 
e. Kudenchuk, 1999  
f. Serious concerns for risk of bias and failure to adhere to the intention-to-treat principle in superiority trials.  
g. Patients enrolled 1994-1997, used 1992 AHA guidelines (2 slow initial breaths, 80-100 compressions/min of 1.5-2.5 inches, using monophasic defibrillators to delivered stacked 
shocks of escalating energy, no TTM), used polysorbate 80 as placebo (not an inactive placebo) .  
h. Kudenchuk, 2016  
i. The sample size and number of events do not meet the optimal information size criteria.  
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Table 3 
Question: Lidocaine compared with Placebo for shockable cardiac arrest in adults 
Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studie
s 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideratio
ns 
Lidocain
e 
Placebo 
Relativ
e 
(95% 
CI) 
Absolut
e 
(95% 
CI) 
Survival to hospital discharge 
1 a randomise
d trials  
not 
seriou
s  
not serious  not serious  serious b none  233/985 
(23.7%)  
222/105
6 
(21.0%)  
RR 
1.13 
(0.96 to 
1.32)  
27 more 
per 
1,000 
(from 8 
fewer to 
67 
more)  
⨁⨁⨁◯ 
MODERAT
E 
CRITICAL  
Survival to hospital discharge with good Neurological function 
1 a randomise
d trials  
not 
seriou
s  
not serious  not serious  serious b none  172/984 
(17.5%)  
175/105
5 
(16.6%)  
RR 
1.05 
(0.87 to 
1.28)  
8 more 
per 
1,000 
(from 
22 
fewer to 
46 
more)  
⨁⨁⨁◯ 
MODERAT
E 
CRITICAL  
Return of Spontaneous Circulation (ROSC) 
11 
 
Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studie
s 
Study 
design 
Risk 
of 
bias 
Inconsistenc
y 
Indirectnes
s 
Imprecisio
n 
Other 
consideratio
ns 
Lidocain
e 
Placebo 
Relativ
e 
(95% 
CI) 
Absolut
e 
(95% 
CI) 
1 a randomise
d trials  
not 
seriou
s  
not serious  not serious  not serious  none  396/992 
(39.9%)  
366/105
9 
(34.6%)  
RR 
1.16 
(1.03 to 
1.29)  
55 more 
per 
1,000 
(from 
10 more 
to 100 
more)  
⨁⨁⨁⨁ 
HIGH  
IMPORTAN
T  
CI: Confidence interval; RR: Risk ratio 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Kudenchuk, 2016  
b. The effect estimate is imprecise with confidence intervals including the no effect value “1” and the sample size does not meet the optimal information size 
criteria. 
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 Table 4 
Question: Amiodarone compared to Lidocaine for shockable cardiac arrest in adults 
Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studie
s 
Study 
design 
Risk 
of 
bias 
Inconsisten
cy 
Indirectne
ss 
Imprecisio
n 
Other 
consideratio
ns 
Amiodaro
ne 
Lidocain
e 
Relativ
e 
(95% 
CI) 
Absolut
e 
(95% 
CI) 
Survival to hospital discharge - combined 
2 a randomise
d trials  
seriou
s b 
not serious  very 
serious c 
serious d none  246/1150 
(21.4%)  
238/1152 
(20.7%)  
RR 
1.04 
(0.89 to 
1.22)  
8 more 
per 
1,000 
(from 
23 
fewer to 
45 
more)  
⨁◯◯◯ 
VERY 
LOW  
CRITICAL  
Survival to hospital discharge - Lidocaine with polysorbate 80 
13 
 
Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studie
s 
Study 
design 
Risk 
of 
bias 
Inconsisten
cy 
Indirectne
ss 
Imprecisio
n 
Other 
consideratio
ns 
Amiodaro
ne 
Lidocain
e 
Relativ
e 
(95% 
CI) 
Absolut
e 
(95% 
CI) 
1 e randomise
d trials  
seriou
s b 
not serious  very 
serious c 
serious d none  9/180 
(5.0%)  
5/167 
(3.0%)  
RR 
1.67 
(0.57 to 
4.88)  
20 
more 
per 
1,000 
(from 
13 
fewer to 
116 
more)  
⨁◯◯◯ 
VERY 
LOW  
CRITICAL  
Survival to hospital discharge - Lidocaine without polysorbate 80 
1 f randomise
d trials  
not 
seriou
s  
not serious  not serious  serious d none  237/970 
(24.4%)  
233/985 
(23.7%)  
RR 
1.03 
(0.88 to 
1.21)  
7 more 
per 
1,000 
(from 
28 
fewer to 
50 
more)  
⨁⨁⨁◯ 
MODERAT
E  
CRITICAL  
Survival to hospital discharge with good Neurological function 
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Certainty assessment 
№ of events / № of 
patients 
Effect 
Certainty Importance 
№ of 
studie
s 
Study 
design 
Risk 
of 
bias 
Inconsisten
cy 
Indirectne
ss 
Imprecisio
n 
Other 
consideratio
ns 
Amiodaro
ne 
Lidocain
e 
Relativ
e 
(95% 
CI) 
Absolut
e 
(95% 
CI) 
1 f randomise
d trials  
not 
seriou
s  
not serious  not serious  serious d none  182/967 
(18.8%)  
172/984 
(17.5%)  
RR 
1.08 
(0.89 to 
1.30)  
14 
more 
per 
1,000 
(from 
19 
fewer to 
52 
more)  
⨁⨁⨁◯ 
MODERAT
E  
CRITICAL  
Return of Spontaneous Circulation (ROSC) 
1 f randomise
d trials  
not 
seriou
s  
not serious  not serious  serious d none  350/974 
(35.9%)  
396/992 
(39.9%)  
RR 
0.90 
(0.80 to 
1.01)  
40 
fewer 
per 
1,000 
(from 
80 
fewer to 
4 more)  
⨁⨁⨁◯ 
MODERAT
E  
IMPORTAN
T  
CI: Confidence interval; RR: Risk ratio 
Explanations 
a. 1) Dorian, 2002; 2) Kudenchuk, 2016.  
15 
 
b. Serious concerns regarding risk of bias.  
c. Dorian, 2002 used a lidocaine formulation that contained an active substance (polysorbate 80).  
d. The effect estimate is imprecise with confidence intervals including the no effect value “1” and the sample size does not meet the optimal information size 
criteria.  
e. Dorian, 2002  
f. Kudenchuk, 2016  
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Figure 1 
 
 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through  
database searching 
N = 13868 
Additional records identified  
through other sources 
N = 8 
Records after duplicates removed 
N = 9371 
Records screened 
N = 9371 
Records excluded 
N = 8962 
Full-text articles assessed  
for eligibility 
N = 409 
Full-text articles excluded, 
with reasons 
N = 371 
Randomized Control Trials 
included in quantitative 
synthesis (adult) 
N = 14 studies (16 papers) 
 
Observational Studies 
included in quantitative 
synthesis (adult) 
N = 18 studies (21 papers) 
 
Observational Studies 
included in quantitative 
synthesis (pediatric) 
N = 1 
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Figure 2.1 
Effectiveness of anti-arrhythmic drugs (RCTs; Intervention vs. Placebo) 
Survival to hospital discharge with good Neurological function/ 30 days 
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Figure 2.2 
Survival to hospital discharge / 30 days 
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Figure 2.3 
Return of Spontaneous Circulation (ROSC) 
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Figure 3.1  
Effectiveness of anti-arrhythmic drugs (RCTs; Head to Head trials) 
Survival to hospital discharge with good Neurological function/ 30 days 
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Figure 3.2 
Survival to hospital discharge / 30 days 
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Figure 3.3 
Return of Spontaneous Circulation (ROSC) 
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Figure 3.4 
 
Recurrence of pVT/VF 
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Figure 4.1 
Effectiveness of anti-arrhythmic drugs (Observational studies; Intervention vs. Standard Care) 
Survival to hospital discharge / 30 days (Observational studies) 
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Figure 4.2 
Long term survival (1 year; Observational studies) 
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Figure 4.3 
Return of Spontaneous Circulation (ROSC; Observational studies) 
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Figure 4.4 
Survival to hospital discharge with good Neurological function/ 30 days (Observational studies) 
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Figure 5.1 
Effectiveness of anti-arrhythmic drugs (Observational studies; Head to Head comparison) 
Survival to hospital discharge / 30 days (Observational studies) 
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Figure 5.2 
Long term survival (1 year; Observational studies) 
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Figure 5.3 
Return of Spontaneous Circulation (ROSC; Observational studies) 
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Figure 5.4 
Survival to hospital discharge with good Neurological function/ 30 days (Observational studies) 
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Figure 5.5 
Survival to hospital discharge / 30 days (Pediatric population; Observational studies) 
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Figure 5.6 
Return of Spontaneous Circulation (ROSC - Pediatric population; Observational studies) 
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Figure 5.7 
Survival to hospital discharge / 30 days (Pediatric population; Observational studies) 
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Figure 5.8 
Return of Spontaneous Circulation (ROSC - Pediatric population; Observational studies) 
 
 
 
 
 
 
